Boston Scientific Co. (NYSE:BSX) is Orbimed Advisors LLC's 2nd Largest Position

Orbimed Advisors LLC reduced its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,160,300 shares of the medical equipment provider's stock after selling 112,700 shares during the period. Boston Scientific accounts for about 6.2% of Orbimed Advisors LLC's portfolio, making the stock its 2nd largest holding. Orbimed Advisors LLC owned 0.21% of Boston Scientific worth $282,278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Boston Scientific by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 321,764 shares of the medical equipment provider's stock worth $28,740,000 after buying an additional 18,146 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in Boston Scientific in the fourth quarter valued at $44,214,000. Guardian Wealth Advisors LLC NC raised its position in shares of Boston Scientific by 8.6% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 2,598 shares of the medical equipment provider's stock worth $232,000 after purchasing an additional 205 shares during the period. Gen Wealth Partners Inc acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $72,000. Finally, Gotham Asset Management LLC increased its holdings in shares of Boston Scientific by 43.7% during the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock valued at $1,021,000 after purchasing an additional 3,475 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Evercore ISI raised their price target on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. UBS Group lifted their price objective on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Raymond James boosted their target price on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Morgan Stanley raised their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Twenty-three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $114.52.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the business's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. This represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 288,497 shares of company stock worth $29,791,055 in the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Down 0.1%

NYSE BSX opened at $102.76 on Tuesday. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17. The firm has a market cap of $152.02 billion, a PE ratio of 82.21, a P/E/G ratio of 2.79 and a beta of 0.68. The business's fifty day simple moving average is $98.64 and its 200-day simple moving average is $96.19. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same period last year, the firm earned $0.56 earnings per share. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. As a group, equities analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.